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Abstract
Twenty-seven nanopeptides derived from the matrix (M) protein of porcine reproductive and respiratory syndrome
virus (PRRSV) were screened for their ability to elicit a recall interferon-g (IFN-g) response from the splenocytes of
BALB/c mice following DNA vaccination and a booster vaccination with recombinant vaccinia virus rWR-PRRSV-M.
We identified two peptides (amino acid residues K93FITSRCRL and F57GYMTFVHF) as CD8
+ cytotoxic T lymphocyte
(CTL) epitopes. These peptides elicited significant numbers of IFN-g secreting cells, compared with other M
nonapeptides and one irrelevant nonapeptide. Bioinformatics analysis showed that the former is an H-2K
d-restricted
CTL epitope, and the latter is an H-2D
d-restricted CTL epitope. Multiple amino acid sequence alignment among
different PRRSV M sequences submitted to GenBank indicated that these two CTL epitopes are strongly conserved,
and they should therefore be considered for further research on the mechanisms of cellular immune responses to
PRRSV.
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1. Introduction
Porcine reproductive and respiratory syndrome virus
(PRRSV) is one of the most important swine viral patho-
gens, and has caused significant economic losses to the
swine industry worldwide. Characterization of field
isolates suggested that PRRSV are genetically diverse,
and this genetic variation increases the difficulty of
developing effective vaccines. Based on significant
sequence differencesPRRS viruses are grouped into two
distinct genotypes, European isolate (Lelystad virus, LV)
and North American isolate (VR-2332) [1]PRRSV has
two major structural proteins, GP5 and M, encoded by
O R F s5a n d6 ,r e s p e c t i v e l y .G P 5 ,t h em o s ti m p o r t a n t
neutralizing antigen of PRRSV, has the highest genetic
diversity among isolates [2]. And, recent studies in
Yorkshire × Landrace crossed and outbred pigs, showed
that there are two immuno-dominant T-cell epitopes
derived from the GP5 protein: L117AALICFVIRLAKNC
and K149GRLYRWRSPVII/VEK [3]. The M protein,
which contains highly conserved amino acid sequences,
also has very good immunogenicity and is associated
with protection against PRRSV infection. DNA vaccina-
tions have also revealed that M is the most potent indu-
cer of T lymphocyte proliferation [4].
At present, effective vaccination strategies for the
prevention and control of PRRSV infection are not
available. Vaccines based on inactivated PRRSV virus
have been ineffective at inducing protective immune
responses. Live-attenuated PRRSV vaccines can provide
protection against this pathogen, but have been
observed to revert to virulence [5], restricting the
application of this vaccination approach. The rational
development of future PRRSV vaccines will necessitate
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and cellular immune responses that occur during
PRRSV infection, and should aim to induce a broad
immune responses that accommodates the plasticity of
the major antigenic sites. Recent research has indicated
that cell-mediated immunity may play a very important
role in the clearance of PRRSV [6]. Major histocompat-
ibility complex (MHC) I restricted cytotoxic T lympho-
cytes (CTLs) can kill virus-infected cells and eliminate
potential sources of new virus [7]. Hence, identification
of CTL epitopes is crucial in the design of synthetic
vaccines, and a number of studies have successfully
identified pathogen-derived T cell epitopes [8-11].
Unlike many other pathogens, there is limited knowl-
edge of the specific PRRSV-derived peptides targeted by
T-cells. In the current study, we report the identification
of CTL epitopes from the PRRSV (Ch-1a strain) M pro-
tein in a mouse model. We screened peptides derived
from the PRRSV M protein for their ability to induce
interferon (IFN)-g in splenocytes harvested from BALB/
c mice following DNA vaccination and a booster vacci-
nation with recombinant vaccinia virus expressing M
protein. The screen identified two peptides that elicited
IFN-g production in CD3
+CD8
+ splenocytes of vacci-
nated mice. A multiple amino acid sequence alignment
among different PRRSV M proteins indicates that these
two peptides are strongly conserved across multiple
PRRSV strains and therefore should be considered for
further research.
2. Materials and methods
2.1. Viruses and cell lines
The PRRSV Ch-1a strain, the vaccinia virus WR strain,
and the Akabane virus OBE-1 strain were part of our
laboratory collection. The former was propagated in
Marc-145 cells, and the latter two were propagated in
BHK-21 cells, respectively, and these two cell lines were
cultured in DMEM (Invitrogen) supplemented with 10%
of fetal calf serum (FCS, Invitrogen) in a humidified
37°C, 5% CO2 incubator.
2.2. Cloning of PRRSV M and murine ubiquitin (Ub) genes
Total RNA was extracted from the PRRSV CH-1a strain
and the spleens of BALB/c mice. Full length cDNAs
were amplified based on the complete open reading
frames (ORFs) of M and ubiquitin (Ub) following
reverse transcription (GenBank accession numbers
AY032626 and AZ033428) using the M-F and M-R pri-
mers pair or the Ub-F and Ub-R primer pair (Table 1).
The full length cDNAs were cloned into the pMD18-T
vector (TaKaRa) and are referred to as pMD-M and
pMD-U, respectively.
2.3. The expression of a truncated PRRSV M gene
An indirect enzyme-linked immunosorbent assay
(iELISA) method was established to evaluate specific
antibody against M protein. A truncated M protein (85-
174aa), which was used as the coating antigen, was
expressed and purified using a prokaryotic expression
system. The truncated M gene cDNA was amplified from
pMD-M using the truncated-M-F and truncated-M-R
primers (Table 1), ligated into pGEX-6P-1 (GE Health-
care), and subsequently named pGEX-M. For protein
expression, pGEX-M was transformed into E.coli BL21
(DE3) and recombinant protein expression was induced
with 0.5 mM IPTG. The samples were harvested by cen-
trifugation and the pellets were resuspended with phos-
phate buffered saline (PBS, PH 8.0). After being analyzed
by sodium dodecyl sulfatepolyacrylamide gel electrophor-
esis (SDS-PAGE) and Western blot with anti-PRRSV-M
monoclonal antibody (our laboratory collection), the
fusion-expressed truncated M protein was purified by
GST tag according to the manufacturer’s instructions
(GE Healthcare). Finally, the concentration of the
purified protein was determined using a Bradford kit
(Bio-Rad) according to the manufacturer’s instructions.
Table 1 Primers designed for PCR
primer Sequence (5’-3’) Note
M-F CCCAAGCTTAGCATGGGGTCGTCTCTAGA Hind III
M-R CCGCTCGAGCTATTTGGCATATTTGACA XhoI
Ub-F TCAGGATCCGCCGCCGCCATGCAGATTTTCGTG BamH I
Ub-R GGAGCCTGGAGAAGCACCTCTCAGGCGAAGGAC
Truncated-M-F CCGGAATTCATGGGAGTGTACTCGGCCATAG EcoR I
Truncated-M-R CCGCTCGAGCTATTTGGCATATTTGAC Xho I
Fusion-M-Ub-F TCTCCAGGCTCCATGGGGTCGTCTCTA Linker
Fusion-M-Ub-R GGAGCCTGGAGAAGCACCTCTCAGGCGAAGGAC Linker
pSC11-M-F ATAGTCGACGCCGCCGCCATGGGGTCGTCTCTAG SalI
pSC11-M-R GCCGTCGACCTATTTGGCATATTTGACAAGGTTTAC SalI
P7.5-F GCACGGTAAGGAAGTAGAAT
Note: The bold letter of primers are start or stop codons; the underlined sequence of primers represents the Kozak motif or the linker sequence.
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pVAX1-Ub-M
The Ub and M genes were fused using splicing by over-
lapping extension PCR (SOE-PCR). The Ub and M
genes were amplified from pMD-U and pMD-M with
the primer pairs Ub-F and Fusion-M-Ub-R and Fusion-
M-Ub-F and M-R, respectively (Table 1). The fusion
gene product, referred to as Ub-M, was amplified from
the purified PCR products with Ub-F and M-R and
inserted into the eukaryocyte expression vector pVAX1,
and was named pVAX1-Ub-M.
2.5. Expression of pVAX1-Ub-M in vitro
In vitro expression of the Ub-M was demonstrated by
transient transfection of BHK-21 cells using FuGene
6 (Roche) according to the manufacturer’si n s t r u c t i o n s .
Ub-M protein expression was detected by indirect
immunofluorescence analysis (IFA). An anti-PRRSV-M
monoclonal antibody and a FITC-conjugated rabbit
anti-mouse IgG secondary antibody (Sigma) were used
for IFA detection of M protein. Fluorescence was
observed using a fluorescence microscope (LEICA DM
IRE2).
2.6. Construction of recombinant vaccinia virus
2.6.1. Construction of the transferring plasmid pSC11-M
The transferring vector pSC11 (our laboratory collec-
tion), which is composed of the early promoter P7.5 and
late promoter P11 of vaccinia virus, and the LacZ and
Amp genes controlled by the promoter P11 as the
reporter genes, was used in this study. To construct the
transferring vector pSC11-M, the complete M gene was
amplified with the pSC11-M-F and pSC11-M-R primer
pair (Table 1) and inserted into the pSC11. The primer
P7.5-F (Table 1), derived from promoter P7.5 sequence,
was used for directional identification and the positive
clones, which were subsequently named pSC11-M.
2.6.2. Homologous recombination and selection of the
recombinant virus
Homologous recombination was performed by lipofec-
tin-mediated co-transfection of the transferring plasmid
pSC11-M and the WR strain vaccinia virus into 80%
confluent TK
-143 cells cultured in MEM medium
containing 25 μg/ml BrdU (Sigma). The viruses were
collected after the appearance of cytopathic effect (CPE),
and recombinant vaccinia virus was purified according
to the expression of LacZ gene.
2.7. Identification of the recombinant virus
2.7.1. Western blot analysis of the recombinant virus
Western blot analysis was performed as described pre-
viously [12]. Briefly, a BHK-21 cell layer was infected
with rWR-PRRSV-M recombinant vaccinia virus or the
vaccinia virus WR strain at a multiplicity of infection
(MOI) of 0.1. Cells were harvested 3 days post-infection,
and total cell lysates were prepared with lysis buffer
(10 mM Tris-Cl pH 7.4, 1 mM MgCl2, 0.5% NP40, 20
μg/ml DNase I). Cell lysates were separated by SDS-PAGE
a n dw e r es u b s e q u e n t l yt r a nsferred to a membrane for
Western blot analysis using an anti-PRRSV-M monoclonal
antibody, HRP-conjugated goat anti-mouse IgG secondary
antibody (Bio-Rad), and DAB substrate. The positive
recombinant virus was named rWR-PRRSV-M.
2.7.2. IFA of the recombinant virus
The expression of M was further confirmed by IFA.
Briefly, BHK-21 cells were infected with either rWR-
PRRSV-M or the vaccinia virus WR strain when the
BHK-21 cells reached 70-80% confluence in a 24-well
plate. M protein expression was evaluated by IFA 3 days
post infection using the anti-PRRSV-M monoclonal
antibody followed by a FITC-conjugated rabbit anti-
mouse IgG secondary antibody (Sigma). Specific fluores-
cence was observed using a fluorescence microscope
(LEICA DM IRE2).
2.8. Prediction and synthesis of M protein CTL epitopes in
BALB/c mice
The sequences of M were screened for potential H2-K
d/
H2-D
d/H2-L
d 9-mer epitopes using the algorithms from
the SYFPEITHI website [13], the HLA peptide binding
prediction website (BIMAS) [14] and PRED
BALB/c [15].
The 27 peptides (Table 2), with highest binding score
(BS) as predicted by each algorithm, were synthesized by
Scilight Biotechnology LLC (Beijing, China) and purified
to a purity > 95% using high performance liquid chroma-
tography (HPLC).
2.10. Vaccination using a DNA prime-recombinant
vaccinia virus boost strategy
All animal experiments were performed according to
national and institutional guidelines. One hundred and
ninety female BALB/c mice (Vital River Laboratory
Animal Technology Co., Beijing, China) were main-
tained in isolation cages at the Experimental Animal
Center of Harbin Veterinary Research Institute (Harbin,
China). Mice were divided into three groups: the
pVAX1-Ub-M vaccination group (n = 120), the pVAX1
control vaccination group (n = 35) and the PBS control
vaccinated group (n = 35).
The plasmid DNA used for immunization was purified
using the EndoFree Mega plasmid preparation kit
(Qiagen). The pVAX1-Ub-M and pVAX1 cohorts were
intramuscularly (i.m.) vaccinated with 100 μg pVAX1-
Ub-M or pVAX1 plasmid DNA in 100 μlP B S ,r e s p e c -
tively. The PBS control group received an i.m. injection
of 100 μL PBS. Each group was vaccinated four times at
3-week intervals. To enhance the specific CTL responses
to M protein, the mice received an intraperitoneal
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day 7 following the fourth DNA vaccination. At the
same time, five mice from the pVAX1 and PBS vaccina-
tion groups were also inoculated intraperitoneally with
0.1 MOI of rWR-PRRSV-M on day 7 following the
fourth vaccination in order to compare the specific anti-
body raised against M protein of different experimental
groups following vaccination with rWR-PRRSV-M. All
procedures were conducted with the protocols approved
by Experimental Animal Center of Harbin Veterinary
Research Institute (HVRI) of the Chinese Academy of
Agricultural Sciences (CAAS).
2.11. ELISA antibody response in mice after immunization
To investigate the specific antibody response, serum
samples was obtained from vaccinated mice 7 days after
each DNA vaccination and 3 days after boosting with
rWR-PRRSV-M. An iELISA was performed according to
methods described previously [16]. The purified M
protein was used as the coating antigen, the tested sera
applied at a 1:10 dilution, and an HRP-conjugated goat
anti-mouse IgG antibody (Bio-Rad) used as the secondary
antibody. The microplates were developed using ortho-
phenylene diamine (OPDA, AMERSCO) and H2O2 for
10 min, after which the reaction was stopped by the
addition of 1 M H2SO4.F i n a l l y ,t h eo p t i c a ld e n s i t y( O D )
was read at 492 nm. An anti-PRRSV-M monoclonal anti-
body was used as a positive control. Serum containing
antibodies against Akabane virus and the sera of control
group mice served as negative controls.
2.12. In vitro stimulation of splenocytes
Isolated splenocytes were added to U-bottomed 96-well
plates (Corning Inc) at 10
6 cells/well in 100 μL complete
RPMI-1640 medium supplemented with 10% FCS.
The cells were then mixed with 100 μl media containing
Table 2 Predicted M protein peptides chemically synthesized and screened to identify CTL epitopes
Bioinformatics Methods
SYFPEITHI BIMAS PRED
BALB/c
Peptides Bingding score Peptides Bingding score Peptides Bingding score
H-2K
d K93FITSRCRL BS = 23 K93FITSRCRL BS = 2304.000 K93FITSRCRL BS = 9.70
T25YTPVMIYA BS = 24 T25YTPVMIYA BS = 72.000 T25YTPVMIYA BS = 5.3
S12TAPQKVLL BS = 20 S12TAPQKVLL BS = 57.600 S12TAPQKVLL BS = 6.10
S140TTVNGTLV BS = 19 S 140TTVNGTLV BS = 14.400 S 140TTVNGTLV BS = 6.10
T146LVPGLKGL BS = 19 T146LVPGLKGL BS = 115.200 T146LVPGLKGL BS = 9.10
A21FSITYTPV BS = 18 A21FSITYTPV BS = 345.600 A21FSITYTPV BS = 9.54
R40LLGLLHLL BS = 18 R40LLGLLHLL BS = 96.00 R40LLGLLHLL BS = 7.80
L34KVSRGRLL BS = 17 L34KVSRGRLL BS = 9.600 L34KVSRGRLL BS = 5.64
H64FQSTNRVA BS = 17 H64FQSTNRVA BS = 28.800 H64FQSTNRVA BS = 5.64
C102LLGRKYIL BS = 17 C102LLGRKYIL BS = 96.00 C102LLGRKYIL BS = 7.84
Q16KVLLAFSI BS = 16 L162KVSRGRLL BS = 11.520 L162KVSRGRLL BS = 5.80
L162KVSRGRLL BS = 16 L162KVSRGRLL BS = 0.012 L162KVSRGRLL BS = 6.10
S23ITYTPVMI BS = 14 S23ITYTPVMI BS = 48.000 S23ITYTPVMI BS = 8.50
H-2D
d Y26TPVMIYAL BS = 20.000 Y26TPVMIYAL BS = 9.82
F57GYMTFVHF BS = 7.200 F57GYMTFVHF BS = 10.00
T13APQKVLLA BS = 12.000 T13APQKVLLA BS = 8.58
Q164GVVNLVKY BS = 2.000 Q164GVVNLVKY BS = 9.40
F122HPIAANDN BS = 2.400 F122HPIAANDN BS = 9.20
P138GSTTVNGT BS = 0.200 P138GSTTVNGT BS = 9.20
H-2L
d A14PQKVLLAF BS = 24 A14PQKVLLAF BS = 450.000 A14PQKVLLAF BS = 9.38
V148PGLKGLVL BS = 24 V148PGLKGLVL BS = 150.000 V148PGLKGLVL BS = 9.50
D11STAPQKVL BS = 20 D11STAPQKVL BS = 25.000 D11STAPQKVL BS = 7.50
Y86SAIETWKF BS = 20 Y86SAIETWKF BS = 50.000 Y86SAIETWKF BS = 7.50
E117SAAGFHPI BS = 20 E117SAAGFHPI BS = 6.500 E117SAAGFHPI BS = 4.70
T96SRCRLCLL BS = 19 T96SRCRLCLL BS = 7.500 T96SRCRLCLL BS = 7.60
G139STTVNGTL BS = 18 G139STTVNGTL BS = 25.000 G139STTVNGTL BS = 7.40
F22SITYTPVM BS = 15 F22SITYTPVM BS = 25.000 F22SITYTPVM BS = 7.00
Note: The 27 peptides with highest binding score (BS) as predicted by each algorithm are shown, starting with the peptide giving the highest score at the top
for each protein. Sequences of 9 mers are given from BIMAS, SYFPEITHI and PRED
BALB/c predictions, respectively. The N-terminal amino acid position is indicated
for epitopes predicted from the whole M protein.
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μg/ml, or phorbol-12-myristate-13-acetate (PMA 10 ng/
mL) and ionomycin (500 ng/mL) as a positive control.
Cells incubated in medium alone or with a peptide
derived from the infectious bronchitis virus (IBV) H52
strain [17] were used as negative controls. Following a
12 h incubation at 37°C, 10 uM monensin (Sigma) was
added and the splenocytes were incubated for an addi-
tional 4 h at 37°C before staining.
2.13. Surface antigen staining and intracellular
cytokine staining (ICS)
The number of CD3
+CD8
+ T cells producing IFN-g on
days 3, 5 and 12 after boosting with rWR-PRRSV-M was
determined using flow cytometric analysis. ICS analysis
was performed using a FACSCalibur flow cytometer (BD)
according to the methods described previously [11].
Twenty mice were tested from the group vaccinated with
pVAX1-Ub-M, and five mice from the groups vaccinated
with pVAX1 and PBS were tested at each time point. The
splenocytes from each vaccination group were counted,
pooled, and stimulated in vitro with M protein-derived
peptides, as detailed in section 2.12. Ten thousand CD3
+
T lymphocytes were acquired per sample and the number
of IFN-g-secretion CD3
+CD8
+ T cells were enumerated.
The CD3
+CD8
+ lymphocytes that expressed IFN-g fol-
lowing peptide stimulation were considered to be pep-
tide-specific CTLs. Specific CTL responses were
evaluated as the increase in the number of CD3
+CD8
+IFN-g
+ cells. Reagents used include PerCP-conjugated
CD3e, PE-conjugated CD8a and FITC-conjugated IFN-g,
and BD Cytofix/Cytoperm™, all purchased from Becton,
Dickinson & Co (BD).
2.14. Confirmation of ICS results by ELISpot assay
To further confirm the results of the ICS, the other sixty
mice from the group vaccinated with pVAX1-Ub-M and
thirty mice from the groups vaccinated with pVAX1 and
PBS were tested by the IFN-g ELISPOT assay at three
different time points (as detailed in section 2.13). Data
are expressed as the number of IFN-g-secreting cells per
two hundred thousand splenocytes. Peptide-specific
IFN-g ELISPOT responses were considered to be posi-
tive if the response (minus media background) was ≥ 3-
fold above the media response and ≥ 50 spot-forming
cells (SFC)/2 × 10
5 splenocytes were registered.
2.15. Statistical analysis
The iELISA results, the percentage of IFN-g positive
CD3
+CD8
+ T lymphocytes and the number of spots per
2×1 0
5 splenocytes were analyzed using the analysis of
variance (ANOVA), and a probability value below 0.05
was considered significant.
3. Results and Discussion
3.1. The truncated expression of PRRSV M
As the full-length M protein is difficult to express in
vitro, we expressed a truncated version of M that lacks
84 hydrophobic amino acids at the N-terminus. SDS-
PAGE analysis showed that cells transformed with the
pGEX-M expression vector produced a large amount of
protein with a molecular mass of approximately 36 KDa,
consistent with the expected molecular weight of the
truncated M protein fused with a GST tag (data not
shown). Western blot analysis using an anti-PRRSV-M
antibody confirmed the expression and identity of the
truncated M protein fused with a GST tag (Additional
file 1, Fig. S1).
3.2. Expression of pVAX1-Ub-M in vitro
The Ub Proteasome Pathway (UPP) is the principal
mechanism for protein catabolism in the mammalian
cytosol and nucleus. In order to enhance the
Ub-mediated degradation efficiency of M protein, we
expressed a Ub-M fusion protein in BHK-21 cells
using the eukaryotic expression plasmid pVAX1-Ub-M,
in which the Ub coding sequence was fused in-frame
with the PRRSV M coding sequence. Following transi-
ent transfection of BHK-21 cells with the pVAX1-
Ub-M plasmid, the Ub-M fusion protein was expressed
and accumulated predominantly in the cytoplasm
(Additional file 2, Fig. S2).
3.3. Identification of the recombinant vaccinia virus
Immunization strategies that prime and boost with recom-
binant DNA vectors encoding antigens have been shown
to elicit T-cell immunity against HIV in non-human pri-
mates [18], and more recently, in humans [19]. Therefore,
we used a DNA vector encoding the PRRSV M protein to
immunize mice in order to generate and characterize M
protein-reactive CD8
+ T cells. The recombinant vaccinia
virus rWR-PRRSV-M drove expression of an M protein
with the expected molecular weight when transfected into
BHK-21 cells (Additional file 3, Fig. S3). IFA confirmed
expression of M protein following transfection of BHK-21
cells, and revealed M protein accumulation in the
cytoplasm (Additional file 4, Fig. S4).
3.5. Detection of antibodies against M protein by ELISA
M protein-specific serum antibody increased steadily
from the second to the fourth DNA vaccination with
the pVAX1-Ub-M vector which drives M protein
expression in vivo (Additional file 5, Fig. S5), indicating
that DNA vaccination elicited M protein-specific
immune responses as expected. A subsequent booster
vaccination with the recombinant vaccinia virus, rWR-
PRRSV-M, elicited a further increase in PRRSV-specific
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contrast, control mice vaccinated with pVAX1-only or
PBS-only did not show significant increases in M pro-
tein-specific antibody titers after the booster vaccination
with rWR-PRRSV-M (P > 0.05, Additional file 5,
Fig. S5). Overall, mice vaccinated with pVAX1-Ub-M
generated significantly higher M protein-specific anti-
body titers compared to mice vaccinated with pVAX1
or PBS (P < 0.01, Additional file 5, Fig. S5). These
results indicate that rWR-PRRSV-M amplifies the pro-
tective effects of DNA vaccination and reveals the
advantage of this priming-boosting strategy. DNA vacci-
nation with pVAX1-Ub-M likely drives the differentia-
tion of memory B cells which are subsequently activated
by rWR-PRRSV-M following the booster immunization,
resulting in increased M-specific antibody titers. Mice
vaccinated with PBS and pVAX1 would not be expected
to generate M protein-reactive memory B cells, account-
ing for a less pronounced increase in M protein-specific
antibody titers following rWR-PRRSV-M innoculation.
3.6. Identification of PRRSV-M CTL epitopes by ICS and
ELISPOT
In this study we identified potential CTL epitopes in
BALB/c mice vaccinated with pVAX1-Ub-M and
boosted with rWR-PRRSV-M. The frequency and num-
ber of CD3
+CD8
+ T cells that produced IFN-g following
stimulation with peptides derived from PRSSV M pro-
tein was enumerated using ICS and ELISPOT assays.
Using these approaches, we identified two peptides from
PRSSV M protein that elicited IFN-g production from
the splenocytes of vaccinated mice. As shown in Figure
1, intracellular IFN-g staining following stimulation of
splenocytes from vaccinated mice with the peptide
K93FITSRCRL and F57GYMTFVHF revealed a popula-
tion of IFN-g producing CD8
+ T cells comprising 4-5%
of the total CD3
+ splenocyte population. In contrast,
unstimulated splenocytes and splenocytes exposed to an
irrevelant peptide did not contain a population of IFN-g
producing CD8
+ T cells (Figure 1, panel B and C). Con-
sistent with the ICS data, peptides K93FITSRCRL and
F57GYMTFVHF elicited IFN-g production from spleno-
cytes of vaccinated mice when measured by ELISPOT,
whereas unstimulated splenocytes and splenocytes
stimulated with an irrelevant peptide did not reveal
IFN-g producing cells (Figure 2). The K93FITSRCRL and
F57GYMTFVHF PRSSV M protein peptides were identi-
fied bioinformatically as H-2K
d and H-2D
d restricted
CTL epitopes (Table 2).
Specific increases in the number of cells producing
IFN-g following stimulation with the peptides
“K93FITSRCRL” and “F57GYMTFVHF” was observed by
day 3 after the booster vaccination with rWR-PRRSV-M
(Figure 1 and 2). Furthermore, splenocytes from mice
vaccinated with pVAX1-Ub-M responded strongly to
“K93FITSRCRL” and “F57GYMTFVHF”,b u tn o to t h e r
M protein-derived peptides, at all time points tested fol-
lowing the booster vaccination with rWR-PRRSV-M.
When the same pattern of reactivity on three different
time points after boosting with rWR-PRRSV-M within
each vaccination group were analyzed statistically using
ANOVA analysis, statistically significant differences
were noted for the peptides “K93FITSRCRL” and
“F57GYMTFVHF” when compared to the other peptides
tested among mice vaccinated and boosted with
pVAX1-Ub-M and rWR-PRRSV-M, respectively (P <
0.01, Figure 3A and 3B). Conversely, and confirming the
specificity of these responses, no difference among the
stimuli was observed with mock-vaccinated (pVAX1)
mice and naïve mice (data not shown).
It is important to recognize that the ICS assay calcu-
lates the percentage of IFN-g
+ cells among CD3
+ T cells
20.23%  0.24% 
B A
0.03%  4.97% 
D C
4.12% 
E
Figure 1 A representative response was obtained from one
mouse on 3 day after boosting with rWR-PRRSV-M, and two M
protein peptides stimulate IFNg
+ production in CD8
+ T cells of
immunized BALB/c mice by ICS. Splenocytes from immunized
BALB/c mice were (A) stimulated with PMA and ionomycin: 20.23%,
(B) left unstimulated: 0.24%, (C) stimulated with an irrelevant
peptide: 0.03%, (D) stimulated with the peptide “K93FITSRCRL“:
4.97%, or (E) stimulated with the peptide “F57GYMTFVHF“: 4.12%,
and were stained with antibodies to identify IFNg production in
CD8
+ T cells by flow cytometry. The % in each data plot represents
the percentage of CD8
+ T cells that secreted IFNg.
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Figure 2 Two M protein peptides stimulate IFNg
+ production in splenocytes from immunized BALB/c mice in an ELISPOT assay.
Splenocytes from immunized BALB/c mice were (A) left unstimulated, (B) stimulated with an irrelevant peptide, (C) stimulated with the peptide
“F57GYMTFVHF“: 54 spots/5 × 105 cells, (D) stimulated with the peptide “K93FITSRCRL“: 81 spots/5 × 105 cells, or (E) stimulated with PMA and
ionomycin (324 spots/5 × 105 cells) to determine the frequency of IFNg-secreting splenocytes.
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Figure 3 A: Summary results of ICS analysis for IFNg
+ production in CD8
+ T cells of immunized BALB/c mice stimulated with a panel
of M protein-derived peptides. B: Summary results of ELISPOT analysis for IFNg
+ production from splenocytes of immunized BALB/c mice
stimulated with a panel of M protein-derived peptides. Finally, one hundred and twenty mice were used to analyze the results from ICS and
ELISPOT. And the same pattern of reactivity on days 3, 5 and 12 after boosting with rWR-PRRSV-M within each vaccination group were analyzed,
and the numbers 1-27 represent different peptides derived from M protein of PRRSV Ch-1a strain; Number 28 is an irrelevant peptide control; NC
is an unstimulated negative control; PC is a PMA + ionomycin stimulated positive control; BC is a background control. Data in the bar graphs (A
and B) are means and standard deviations from the group vaccinated with pVAX1-Ub-M.
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assesses the number of IFN-g
+ cells among all spleno-
cyte cell types (0.05%), and cannot definitively assign the
production of IFN-g to a particular cell type. Thus, the
two assays use different denominators in calculating the
frequency of IFN-g
+ production by splenocytes. Impor-
tantly, each method clearly identified K93FITSRCRL and
F57GYMTFVHF as the only two peptides from a panel
of 27 that elited significant IFN-g production from the
splenocytes of vaccinated mice.
In this study we used BALB/c mice as a model system
to identify CTL epitopes in the M protein of PRSSV to
circumvent limitations derived from shortages of inbred
pigs and a paucity of reagents to evaluate porcine
immune responses. The identification of PRSSV CTL
epitopes in BALB/c mice allow for the future generation
of reagents, such as MHC class I: peptide staining
reagents, that will enable the in-depth investigations of
CD8
+ T cell responses during PRSSV infection and
immuinization. Whether these two epitopes can bind
the SLA class I molecules of pigs remains to be deter-
mined. In some cases, specific peptide epitopes are
known to be recognized by cytotoxic T cells in different
animal species. For instance, the core region of HCV
contains an epitope that is recognized by cytotoxic T
cells of both mice and humans [19]. Further research on
the role of these peptide epitopes in different species is
ongoing in our laboratory.
In conclusion, we identified peptides “K93FITSRCRL”
and “F57GYMTFVHF” from the M protein of PRSSV as
H-2K
d and H-2D
d restricted CTL epitopes, respectively.
In this study, we also developed a mouse model of
PRRSV infection and this will undoubtedly contribute to
our understanding of the cell-mediated immune
responses to PRRSV.
Additional material
Additional file 1: Western blotting results of the recombinant
protein PRRSV-M expressed in E.coli. Fig.S1. Western blotting analysis
of the recombinant protein PRRSV-M expressed in E.coli BL21 (DE3) cells
transformed with the pGEX-M expression vector. SDS-PAGE analysis
showed that cells transformed with the pGEX-M expression vector
produced a large amount of protein with a molecular mass of
approximately 36 KDa, consistent with the expected molecular weight of
the truncated M protein fused with a GST tag (data not shown). And
western blot analysis using an anti-PRRSV-M antibody confirmed the
expression and identity of the truncated M protein fused with a GST tag
(Lane 1), while there was no such signal at the corresponding position of
the negative control sample (Lane 2). Lane M. prestained protein mass
marker; Lane 1. recombinant PRRSV M protein; Lane 2. pGEX-6P-1.
Additional file 2: IFA results of eukaryotic expression plasmid
pVAX1-Ub-M in transfected BHK-21 cells. Fig.S2. IFA result of BHK-21
cells transfected with pVAX1-U-M. BHK-21 cells were transfected with
pVAX1-U-M or empty pVAX1 plasmids. After 36 hours, IFA was performed
using an M protein-specific antibody. A. pVAX1-U-M; B. pVAX1.
(magnifications are × 200).
Additional file 3: Western blot results of recombinant vaccinia virus
rWR-PRRSV-M in infected BHK-21 cell. Fig.S3. Western blot analysis of
BHK-21 cell lysates following infection with rWR-PRRSV-M. BHK-21 cells
were infected with rWR-PRRSV-M or WR strain vaccinia virus. After 72
hours, cell lysates were generated for Western blot using an M protein-
specific antibody. The results showed that the recombinant vaccinia virus
rWR-PRRSV-M drove expression of a complete M protein with the
expected molecular weight (17 KDa) when transfected into BHK-21 cells.
Lane M: prestained protein mass marker; Lane 1. Lysate from cells
infected with rWR-PRRSV-M; Lane 2. Lysate from cells infected with WR
strain vaccinia virus.
Additional file 4: IFA results of recombinant vaccinia virus rWR-
PRRSV-M and vaccinia virus WR strain in infected BHK-21 cell. Fig.
S4. IFA result of BHK-21 cells infected with rWR-PRRSV-M and vaccinia
virus WR strain. BHK-21 cells were infected with (A) rWR-PRRSV-M or (B)
vaccinia virus WR strain. After 72 hours, IFA was performed using an M
protein-specific antibody. (magnifications are × 100).
Additional file 5: ELISA antibody response in mice after
immunization following DNA vaccination and a booster vaccination
with recombinant vaccinia virus. Fig.S5. M protein-specific antibody
responses in mice immunized with PBS, or pVAX1 or pVAX1-U-M DNA,
and boosted with rWR-PRRSV-M. Serum samples was obtained from
vaccinated mice 7 days after each DNA vaccination and 3 days after
boosting with rWR-PRRSV-M, and were evaluated for reactivity to M-
protein in an ELISA based on coating with the truncated M protein fused
with a GST tag. And, the day 0 represents the day of the first DNA
immunization. Statistically significant differences are indicated by “*” or
“**” for p-values < 0.05 or < 0.01, respectively, as determined by ANOVA.
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